0001951635-22-000001.txt : 20221103 0001951635-22-000001.hdr.sgml : 20221103 20221103160845 ACCESSION NUMBER: 0001951635-22-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b ITEM INFORMATION: Investment Company Act Section 3(c) ITEM INFORMATION: Section 3(c)(7) FILED AS OF DATE: 20221103 DATE AS OF CHANGE: 20221103 EFFECTIVENESS DATE: 20221103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Solas BioVentures Emerging Healthcare Fund, LP CENTRAL INDEX KEY: 0001940916 IRS NUMBER: 883266786 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-463813 FILM NUMBER: 221358021 BUSINESS ADDRESS: STREET 1: 412 GEORGIA AVENUE STREET 2: SUITE 201 CITY: CHATTANOOGA STATE: TN ZIP: 37403 BUSINESS PHONE: (423) 243-3460 MAIL ADDRESS: STREET 1: 412 GEORGIA AVENUE STREET 2: SUITE 201 CITY: CHATTANOOGA STATE: TN ZIP: 37403 D 1 primary_doc.xml X0708 D LIVE 0001940916 Solas BioVentures Emerging Healthcare Fund, LP 412 GEORGIA AVENUE SUITE 201 CHATTANOOGA TN TENNESSEE 37403 (423) 243-3460 DELAWARE None None Limited Partnership true 2022 Michael Hoey 412 Georgia Avenue Suite 201 Chattanooga TN TENNESSEE 37403 Executive Officer Promoter Manager of the Investment Manager of the Issuer. Mark D. Hackett 412 Georgia Avenue Suite 201 Chattanooga TN TENNESSEE 37403 Executive Officer Promoter Manager of the Investment Manager of the Issuer. David C. Adair 412 Georgia Avenue Suite 201 Chattanooga TN TENNESSEE 37403 Executive Officer Promoter Manager of the Investment Manager of the Issuer. n/a n/a Solas BioVentures Emerging Healthcare GP, LLC 412 Georgia Avenue Suite 201 Chattanooga TN TENNESSEE 37403 Promoter General Partner of the Issuer. n/a n/a Solas BioVentures Management, LLC 412 Georgia Avenue Suite 201 Chattanooga TN TENNESSEE 37403 Promoter Investment Manager of the Issuer. Pooled Investment Fund Other Investment Fund false Decline to Disclose 06b 3C 3C.7 false 2022-10-21 false true false 5000000 Indefinite 5750000 Indefinite false 1 0 true 0 true 65000 true Organizational Expenses will be reimbursed to the General Partner and Investment Manager. A management fee will paid to the Investment Manager in accordance with the Issuer's offering documents. false Solas BioVentures Emerging Healthcare Fund, LP Mark D. Hackett Mark D. Hackett Manager 2022-11-03